Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 18 Jan 2017
At a glance
- Drugs MK 2206 (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 28 Jan 2016 Planned End Date changed from 1 May 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
- 28 Jan 2016 Planned primary completion date changed from 1 May 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
- 21 May 2014 Planned End Date changed from 1 May 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History